LncRNA Information
ID EL0272 Name CASC2 Aliases C10orf5
Species Homo sapiens Chromosome 10 Start site 118046279
End site 118210153 Chain plus Exon NO. 6
Assembly Ensembl Release 89 Class antisense NCBI accession NR_026939, NR_026940, NR_026941
Ensembl ENSG00000177640 Sequence

Disease Method Sample Expression pattern Dysfunction type Description PMID Source
endometrial cancer N/A N/A N/A mutation CASC2, in a region of common allelic loss at chromosome 10q26 is a novel candidate gene in human endometrial cancer. 15024726 LncRNADisease
glioma qPCR, Luciferase reporter assay etc. glioma tissue, cell lines (U251, U87) down-regulated regulation In this study, we confirmed that CASC2 was lowly expressed in glioma tissues as well as in U251 and U87 glioma cell lines. Overexpression of CASC2 inhibited the malignancy of glioma cells, including proliferation, migration, and invasion, and promoted cell apoptosis.We found that up-regulated CASC2 decreased the expression of miR-21 significantly and there is a reciprocal repression between CASC2 and miR-21 in an Argonaute2-dependent manner. 25446261 Lnc2Cancer
non-small cell lung cancer qRT-PCR, overexpression N/A down-regulated expression CASC2 is involved in the development and progression of NSCLC and shows that CASC2 may be a potential diagnostic and target for new therapies in patients with NSCLC. 26790438

Interaction target Level of interaction Type of interaction Description PMID Source
miR-21 RNA-RNA binding Furthermore,bioinformatics, luciferase reporter assays and pull-down assay confirmed that miR-21 binds to CASC2 in a sequence-specific manner. 25446261